Dear fellow members of GRG,
One of the major impediments to progress in aging research is the way aging is treated from the policy and regulatory perspectives. Some of the largest pharmaceutical companies are very interested in shifting their focus from treatment to prevention; however, since aging research is perceived as an altruistic cause rather than a pressing social and economic necessity, there is no sense of urgency even to develop a set of biomarkers and frameworks for human clinical trials.
Frontiers, a reputable open access publisher agreed to launch a research topic titled “Should we Treat Aging as a Disease? Academic, pharmaceutical, healthcare policy and pension fund perspectives”. We invited some of the top thought leaders with academic background to contribute their research, perspectives and reviews.
Please consider submitting your research on the subject to this research topic and/or forward this call for papers to your colleagues: